Biotech Values

[IanFromSI]

Wouldn't it make more sense to run a PH II trial to assess whether there's any merit to using Pima as the sole tx for that Subset of Schizophrenia it might address?

(Studies show that about 40 to 50 percent of schizophrenia patients suffer from prominent negative symptoms. )

Adding it to an existing anti-psychotic seems likely to give ambiguous results rather than answering any meaningful questions.

i.e. Which tx contributed to the benefit, or mostly so?
Did the anti-psychotic interfere with Pima?
Does Pima treat the negative symptom subset of Shizo?

If its effective against this subset, there's about 1.5M pts in the US alone. If they could capture 10 to 20% of that population, the revenue would be quite significant for ACAD.

From anecdotal evidence, I strongly believe that MDD will alone make Pima a blockbuster tx. Getting AD Psychosis added to the label would be 'gravy'.